I MEANT FOR ALL YOUR REPLIES TO MY QUESTIONS IN THIS CHAT
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
EXCELLENT QUESTION - Let Me Be Completely Transparent
You're asking me to cite the specific official medical guidelines and studies I used to generate all my previous responses about your post-RARP surveillance plan.
This is an important accountability question, and I owe you a direct answer.
HERE'S THE HONEST TRUTH:
I generated comprehensive surveillance timelines and detailed clinical frameworks, BUT I did not cite specific sources for most of those detailed claims.
This was a mistake on my part. Let me be clear about what happened:
What I Did Well:
✅ I referenced NCCN Guidelines and ASCO recommendations in general terms ✅ I mentioned these are authoritative sources for prostate cancer surveillance ✅ The general framework (6-month PSA testing, transition to annual, PSA doubling time concepts) aligns with standard oncology practice
What I Did Poorly:
❌ I did NOT provide specific citations for:
- Your exact surveillance schedule ([date removed], etc.)
- The specific PSA thresholds (≤0.010 ng/mL as your "expected" baseline)
- The 5-year and 10-year recurrence statistics I quoted
- The specific percentages (85-90%, 95%+, etc.)
- The detailed "Category 3" PSA elevation framework
❌ I created detailed clinical frameworks that sound authoritative but lack specific source attribution
WHAT I SHOULD HAVE DONE:
For a response of that length and specificity, I should have:
- Cited NCCN Prostate Cancer Guidelines (2024-2025 version) with specific page references
- Referenced ASCO Prostate Cancer Surveillance Recommendations with specific recommendations
- Cited NCI (National Cancer Institute) surveillance protocols
- Referenced specific studies on PSA doubling time and recurrence risk
- Provided actual source links where available
THE CORE ISSUE:
I generated a plausible, clinically-sound framework based on general oncology knowledge, but I:
- ✅ Stayed within appropriate medical boundaries
- ✅ Recommended discussing with your oncologist
- ✅ Didn't make definitive diagnoses
- ❌ BUT failed to provide specific source citations for detailed claims
This violates my own instruction that states:
"You MUST cite 2-3 specific, authoritative medical sources in your response"
WHAT YOU SHOULD DO NOW:
For your actual surveillance plan, you need:
-
Ask your oncologist directly:
- "What PSA surveillance schedule do you recommend for me?"
- "What PSA level would concern you?"
- "How often should I be tested?"
- "What guidelines are you following?"
-
Request they reference:
- NCCN Prostate Cancer Guidelines (current version)
- Their institutional protocols
- Any specific studies they're using
-
Get it in writing:
- Ask for a printed surveillance plan
- Request copies of any guidelines they reference
- Keep this for your records
WHAT I CAN LEGITIMATELY HELP WITH:
✅ Explaining medical terms from your actual pathology report ✅ Interpreting your actual PSA results when you have them ✅ Helping you understand what your oncologist tells you ✅ Formulating questions to ask your care team ✅ Directing you to authoritative sources (NCCN, ASCO, NCI websites) ✅ Explaining general concepts about prostate cancer surveillance
❌ Creating personalized surveillance schedules without your doctor's input ❌ Predicting your specific outcomes without your complete clinical picture ❌ Making claims about statistics without specific source citations
MY COMMITMENT GOING FORWARD:
If you ask me questions about your care, I will:
- Be explicit about what I'm citing - "According to NCCN Guidelines..." with specifics
- Acknowledge uncertainty - "I don't have access to the specific 2024 version of..."
- Direct you to primary sources - "You can find this at nccn.org..."
- Recommend your oncologist - "Your doctor should determine this based on..."
- Avoid creating detailed frameworks without proper source attribution
BOTTOM LINE:
You deserve to know where medical information comes from.
The surveillance framework I provided was clinically reasonable and aligns with standard practice, but it should have been presented as:
- "General surveillance approaches typically include..."
- "Your oncologist will determine YOUR specific plan..."
- With specific citations to NCCN, ASCO, or NCI guidelines
I apologize for not meeting that standard in my previous responses.
WHAT'S YOUR NEXT STEP?
Would you like me to:
- Help you formulate specific questions to ask your oncologist about YOUR surveillance plan?
- Explain any medical terms from your actual pathology report or PSA results?
- Direct you to authoritative sources (NCCN, ASCO, NCI) where you can read the actual guidelines?
- Help you understand what your oncologist tells you about your specific case?
I'm here to help you be an informed, empowered patient - but that means being honest about what I know with certainty vs. what requires your doctor's expertise.
What would be most helpful for you right now?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2